The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 70 results:
Author Title Type [ Year(Asc)]
Filters: Author is Mantzoros, Christos S  [Clear All Filters]
2023
Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., et al. (2023).  Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.. Endocrine. 81(3), 573-578.
Raptis, D. D., Mantzoros C. S., & Polyzos S. A. (2023).  Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.. Ther Clin Risk Manag. 19, 77-96.
Seo, Y-G., Polyzos S. A., Park K-H., & Mantzoros C. S. (2023).  Fibrosis-4 index predicts long-term all-cause, cardiovascular and liver-related mortality in the adult Korean population.. Clin Gastroenterol Hepatol.
Kouvari, M., Valenzuela-Vallejo L., Guatibonza-Garcia V., Polyzos S. A., Deng Y., Kokkorakis M., et al. (2023).  Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.. Metabolism. 147, 155666.
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., & Mantzoros C. S. (2023).  Sarcopenia: still in relative definition-penia and severe treatment-penia.. Metabolism. 155717.
2022
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Markozannes, G., Ntzani E. E., Tsapas A., Mantzoros C. S., Tsiara S., Xanthos T., et al. (2022).  Dose-related meta-analysis for Omega-3 fatty acids supplementation on major adverse cardiovascular events.. Clin Nutr. 41(4), 923-930.
Polyzos, S. A., Hill M. A., Fuleihan G. El- Hajj, Gnudi L., Kim Y-B., Larsson S. C., et al. (2022).  Metabolism, Clinical and Experimental: seventy years young and growing.. Metabolism. 155333.
Polyzos, S. A., & Mantzoros C. S. (2022).  Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.. Curr Med Res Opin. 38(6), 885-888.
Kouvari, M., Polyzos S. A., Chrysohoou C., Skoumas J., Pitsavos C. S., Panagiotakos D. B., et al. (2022).  Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.. Clin Nutr. 41(6), 1281-1289.
2021
Boutari, C., Polyzos S. A., & Mantzoros C. S. (2021).  Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward.. Metabolism. 122, 154781.
Polyzos, S. A., & Mantzoros C. S. (2021).  Diabetes mellitus: 100 years since the discovery of insulin.. Metabolism. 118, 154737.
Tessier, C. M., Polyzos S. A., Athyros V. G., & Mantzoros C. S. (2021).  Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism. 121, 154796.
Rizos, E. C., Markozannes G., Tsapas A., Mantzoros C. S., & Ntzani E. E. (2021).  Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis.. Heart. 107(2), 150-158.
2020
Polyzos, S. A., Kang E. Seok, Tsochatzis E. A., Kechagias S., Ekstedt M., Xanthakos S., et al. (2020).  Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.. Metabolism. 113, 154413.
Polyzos, S. A., Kang E. Seok, Boutari C., Rhee E-J., & Mantzoros C. S. (2020).  Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.. Metabolism. 154203.
Mintziori, G., Nigdelis M. P., Mathew H., Mousiolis A., Goulis D. G., & Mantzoros C. S. (2020).  The effect of excess body fat on female and male reproduction.. Metabolism. 154193.
Boutari, C., Pappas P. D., Mintziori G., Nigdelis M. P., Athanasiadis L., Goulis D. G., et al. (2020).  The effect of underweight on female and male reproduction.. Metabolism. 107, 154229.
Polyzos, S. A., & Mantzoros C. S. (2020).  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).. Metabolism. 154318.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2020).  Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.. Metabolism. 104, 154144.
2019
Polyzos, S. A., Perakakis N., & Mantzoros C. S. (2019).  Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.. Metabolism. 96, 66-82.
Theocharidou, E., Giouleme O., Anastasiadis S., Markopoulou A., Pagourelias E., Vassiliadis T., et al. (2019).  Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis.. Dig Dis Sci. 64(6), 1686-1694.
Anastasilakis, A. D., Koulaxis D., Upadhyay J., Pagkalidou E., Kefala N., Perakakis N., et al. (2019).  Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls.. Horm Metab Res. 51(2), 112-119.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism. 96, iii-v.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.